Zurcher Kantonalbank Zurich Cantonalbank Has $177,000 Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL)

Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Castle Biosciences, Inc. (NASDAQ:CSTL) by 20.5% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 8,192 shares of the company’s stock after buying an additional 1,395 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Castle Biosciences were worth $177,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Deerfield Management Company L.P. Series C acquired a new stake in Castle Biosciences in the third quarter valued at approximately $15,988,000. Jacobs Levy Equity Management Inc. boosted its holdings in Castle Biosciences by 112.0% in the third quarter. Jacobs Levy Equity Management Inc. now owns 547,403 shares of the company’s stock worth $9,246,000 after purchasing an additional 289,252 shares in the last quarter. Walleye Capital LLC bought a new position in shares of Castle Biosciences in the third quarter worth about $2,885,000. Principal Financial Group Inc. lifted its position in shares of Castle Biosciences by 9.0% during the 3rd quarter. Principal Financial Group Inc. now owns 1,482,170 shares of the company’s stock worth $25,034,000 after purchasing an additional 122,169 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC boosted its stake in Castle Biosciences by 294.4% during the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 148,030 shares of the company’s stock valued at $2,500,000 after purchasing an additional 110,500 shares during the period. Institutional investors and hedge funds own 92.60% of the company’s stock.

Analysts Set New Price Targets

CSTL has been the subject of a number of research analyst reports. Robert W. Baird upped their price target on Castle Biosciences from $33.00 to $34.00 and gave the stock an “outperform” rating in a report on Friday, May 3rd. Scotiabank upped their target price on shares of Castle Biosciences from $33.00 to $37.00 and gave the company a “sector outperform” rating in a research note on Friday, March 1st. Finally, KeyCorp raised their price target on shares of Castle Biosciences from $25.00 to $28.00 and gave the stock an “overweight” rating in a research report on Friday, March 1st.

Castle Biosciences Stock Down 2.5 %

CSTL opened at $23.80 on Wednesday. The company has a market capitalization of $656.98 million, a P/E ratio of -20.69 and a beta of 0.93. The company has a debt-to-equity ratio of 0.02, a current ratio of 9.25 and a quick ratio of 9.02. The firm’s fifty day moving average price is $20.83 and its two-hundred day moving average price is $20.59. Castle Biosciences, Inc. has a fifty-two week low of $9.26 and a fifty-two week high of $26.70.

Castle Biosciences (NASDAQ:CSTL) last issued its earnings results on Wednesday, February 28th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.84) by $0.74. The business had revenue of $66.12 million for the quarter, compared to analyst estimates of $51.32 million. Castle Biosciences had a negative net margin of 12.28% and a negative return on equity of 7.91%. On average, analysts anticipate that Castle Biosciences, Inc. will post -2.41 EPS for the current year.

Insider Buying and Selling at Castle Biosciences

In related news, Director Daniel Bradbury sold 23,323 shares of the firm’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $20.68, for a total transaction of $482,319.64. Following the completion of the transaction, the director now owns 25,907 shares in the company, valued at approximately $535,756.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, insider Derek J. Maetzold sold 2,372 shares of the company’s stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $20.77, for a total value of $49,266.44. Following the sale, the insider now owns 72,101 shares of the company’s stock, valued at approximately $1,497,537.77. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Daniel Bradbury sold 23,323 shares of the stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $20.68, for a total transaction of $482,319.64. Following the sale, the director now owns 25,907 shares of the company’s stock, valued at approximately $535,756.76. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 48,409 shares of company stock valued at $1,011,414. 7.20% of the stock is currently owned by corporate insiders.

About Castle Biosciences

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.